Velsipity

Overview

etrasimod

S1P modulator

• CYP2C8 substrate
• CYP2C9 substrate
• CYP3A4 substrate
• bradycardia
• delays atrioventricular conduction
• hypertensive effects
• immunosuppressive effects
• prolongs QT interval (conditional)

Contraindicated

• adenovirus vaccine, live
Velsipity (etrasimod)

+

adenovirus vaccine, live

1 interaction

Contraindicated

etrasimod + adenovirus vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• BCG live intravesical
Velsipity (etrasimod)

+

BCG live intravesical

1 interaction

Contraindicated

etrasimod + BCG live intravesical

contraindicated: combo may incr. risk of disseminated BCG infection; may decr. immune response (immunosuppressive effects)

• chikungunya vaccine, live
Velsipity (etrasimod)

+

chikungunya vaccine, live

1 interaction

Contraindicated

etrasimod + chikungunya vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• cholera vaccine, live
Velsipity (etrasimod)

+

cholera vaccine, live

1 interaction

Contraindicated

etrasimod + cholera vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• dengue vaccine, live
Velsipity (etrasimod)

+

dengue vaccine, live

1 interaction

Contraindicated

etrasimod + dengue vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• influenza nasal vaccine, live
Velsipity (etrasimod)

+

influenza nasal vaccine, live

1 interaction

Contraindicated

etrasimod + influenza nasal vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• measles/mumps/rubella vaccine, live
Velsipity (etrasimod)

+

measles/ mumps/ rubella vaccine, live

1 interaction

Contraindicated

etrasimod + measles/ mumps/ rubella vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• pimozide
Velsipity (etrasimod)

+

pimozide

1 interaction

Contraindicated

etrasimod + pimozide

contraindicated: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• rotavirus vaccine, live
Velsipity (etrasimod)

+

rotavirus vaccine, live

1 interaction

Contraindicated

etrasimod + rotavirus vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• smallpox vaccine, live
Velsipity (etrasimod)

+

smallpox vaccine, live

1 interaction

Contraindicated

etrasimod + smallpox vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• talimogene laherparepvec
Velsipity (etrasimod)

+

talimogene laherparepvec

1 interaction

Contraindicated

etrasimod + talimogene laherparepvec

contraindicated: combo may incr. risk of disseminated herpetic infection; may decr. immune response (immunosuppressive effects)

• thioridazine
Velsipity (etrasimod)

+

thioridazine

1 interaction

Contraindicated

etrasimod + thioridazine

contraindicated: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• typhoid vaccine, live
Velsipity (etrasimod)

+

typhoid vaccine, live

1 interaction

Contraindicated

etrasimod + typhoid vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• varicella vaccine, live
Velsipity (etrasimod)

+

varicella vaccine, live

1 interaction

Contraindicated

etrasimod + varicella vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• yellow fever vaccine, live
Velsipity (etrasimod)

+

yellow fever vaccine, live

1 interaction

Contraindicated

etrasimod + yellow fever vaccine, live

contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

Avoid/Use Alternative

• abatacept
Velsipity (etrasimod)

+

abatacept

1 interaction

Avoid/Use Alternative

etrasimod + abatacept

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• abemaciclib
Velsipity (etrasimod)

+

abemaciclib

1 interaction

Avoid/Use Alternative

etrasimod + abemaciclib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• abrocitinib
Velsipity (etrasimod)

+

abrocitinib

1 interaction

Avoid/Use Alternative

etrasimod + abrocitinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• acalabrutinib
Velsipity (etrasimod)

+

acalabrutinib

1 interaction

Avoid/Use Alternative

etrasimod + acalabrutinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• acebutolol
Velsipity (etrasimod)

+

acebutolol

1 interaction

Avoid/Use Alternative

etrasimod + acebutolol

consider alternative or monitor BP, HR, ECG, especially when adding acebutolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• adagrasib
Velsipity (etrasimod)

+

adagrasib

1 interaction

Avoid/Use Alternative

etrasimod + adagrasib

avoid combo: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• adalimumab
Velsipity (etrasimod)

+

adalimumab

1 interaction

Avoid/Use Alternative

etrasimod + adalimumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• adenosine
Velsipity (etrasimod)

+

adenosine

1 interaction

Avoid/Use Alternative

etrasimod + adenosine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• afamitresgene autoleucel
Velsipity (etrasimod)

+

afamitresgene autoleucel

1 interaction

Avoid/Use Alternative

etrasimod + afamitresgene autoleucel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• aldesleukin
Velsipity (etrasimod)

+

aldesleukin

1 interaction

Avoid/Use Alternative

etrasimod + aldesleukin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• alectinib
Velsipity (etrasimod)

+

alectinib

1 interaction

Avoid/Use Alternative

etrasimod + alectinib

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• alemtuzumab
Velsipity (etrasimod)

+

alemtuzumab

1 interaction

Avoid/Use Alternative

etrasimod + alemtuzumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• alfentanil
Velsipity (etrasimod)

+

alfentanil

1 interaction

Avoid/Use Alternative

etrasimod + alfentanil

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• amiodarone
Velsipity (etrasimod)

+

amiodarone

1 interaction

Avoid/Use Alternative

etrasimod + amiodarone

if also combined w/ moderate or strong CYP3A4 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT and PR interval prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• anagrelide
Velsipity (etrasimod)

+

anagrelide

1 interaction

Avoid/Use Alternative

etrasimod + anagrelide

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• anakinra
Velsipity (etrasimod)

+

anakinra

1 interaction

Avoid/Use Alternative

etrasimod + anakinra

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• anifrolumab
Velsipity (etrasimod)

+

anifrolumab

1 interaction

Avoid/Use Alternative

etrasimod + anifrolumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• anti-thymocyte globulin
Velsipity (etrasimod)

+

anti-thymocyte globulin

1 interaction

Avoid/Use Alternative

etrasimod + anti-thymocyte globulin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• apalutamide
Velsipity (etrasimod)

+

apalutamide

1 interaction

Avoid/Use Alternative

etrasimod + apalutamide

consider alternative or monitor HR, ECG: combo may decr. etrasimod levels, efficacy; may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• apomorphine
Velsipity (etrasimod)

+

apomorphine

1 interaction

Avoid/Use Alternative

etrasimod + apomorphine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• apraclonidine ophthalmic
Velsipity (etrasimod)

+

apraclonidine ophthalmic

1 interaction

Avoid/Use Alternative

etrasimod + apraclonidine ophthalmic

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• aprepitant
Velsipity (etrasimod)

+

aprepitant

1 interaction

Avoid/Use Alternative

etrasimod + aprepitant

aprepitant 3-day regimen: if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised; aprepitant single dose-regimen OK: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• arsenic trioxide
Velsipity (etrasimod)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

etrasimod + arsenic trioxide

use alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT and PR interval prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Velsipity (etrasimod)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

etrasimod + artemether/ lumefantrine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• articaine
Velsipity (etrasimod)

+

articaine

1 interaction

Avoid/Use Alternative

etrasimod + articaine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• asciminib
Velsipity (etrasimod)

+

asciminib

1 interaction

Avoid/Use Alternative

etrasimod + asciminib

if also combined w/ moderate or strong CYP3A4 inhibitor, avoid combo, especially if asciminib 200 mg bid; otherwise, monitor BP: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• asenapine
Velsipity (etrasimod)

+

asenapine

1 interaction

Avoid/Use Alternative

etrasimod + asenapine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• atazanavir
Velsipity (etrasimod)

+

atazanavir

1 interaction

Avoid/Use Alternative

etrasimod + atazanavir

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT and PR interval prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• atenolol
Velsipity (etrasimod)

+

atenolol

1 interaction

Avoid/Use Alternative

etrasimod + atenolol

consider alternative or monitor BP, HR, ECG, especially when adding atenolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• atidarsagene autotemcel
Velsipity (etrasimod)

+

atidarsagene autotemcel

1 interaction

Avoid/Use Alternative

etrasimod + atidarsagene autotemcel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• avacopan
Velsipity (etrasimod)

+

avacopan

1 interaction

Avoid/Use Alternative

etrasimod + avacopan

avoid combo during and x5wk after etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects; infection risk may be prolonged (hepatic metab. inhibited, additive effects)

• axicabtagene ciloleucel
Velsipity (etrasimod)

+

axicabtagene ciloleucel

1 interaction

Avoid/Use Alternative

etrasimod + axicabtagene ciloleucel

avoid combo during and x5wk after etrasimod tx: combo may decr. axicabtagene ciloleucel efficacy; may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• azacitidine
Velsipity (etrasimod)

+

azacitidine

1 interaction

Avoid/Use Alternative

etrasimod + azacitidine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• azathioprine
Velsipity (etrasimod)

+

azathioprine

1 interaction

Avoid/Use Alternative

etrasimod + azathioprine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• azithromycin
Velsipity (etrasimod)

+

azithromycin

1 interaction

Avoid/Use Alternative

etrasimod + azithromycin

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• baricitinib
Velsipity (etrasimod)

+

baricitinib

1 interaction

Avoid/Use Alternative

etrasimod + baricitinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• basiliximab
Velsipity (etrasimod)

+

basiliximab

1 interaction

Avoid/Use Alternative

etrasimod + basiliximab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• bedaquiline
Velsipity (etrasimod)

+

bedaquiline

1 interaction

Avoid/Use Alternative

etrasimod + bedaquiline

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• belatacept
Velsipity (etrasimod)

+

belatacept

1 interaction

Avoid/Use Alternative

etrasimod + belatacept

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• belimumab
Velsipity (etrasimod)

+

belimumab

1 interaction

Avoid/Use Alternative

etrasimod + belimumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• belinostat
Velsipity (etrasimod)

+

belinostat

1 interaction

Avoid/Use Alternative

etrasimod + belinostat

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• bendamustine
Velsipity (etrasimod)

+

bendamustine

1 interaction

Avoid/Use Alternative

etrasimod + bendamustine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• berotralstat
Velsipity (etrasimod)

+

berotralstat

1 interaction

Avoid/Use Alternative

etrasimod + berotralstat

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• betaxolol
Velsipity (etrasimod)

+

betaxolol

1 interaction

Avoid/Use Alternative

etrasimod + betaxolol

consider alternative or monitor BP, HR, ECG, especially when adding betaxolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• betaxolol ophthalmic
Velsipity (etrasimod)

+

betaxolol ophthalmic

1 interaction

Avoid/Use Alternative

etrasimod + betaxolol ophthalmic

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• bimekizumab
Velsipity (etrasimod)

+

bimekizumab

1 interaction

Avoid/Use Alternative

etrasimod + bimekizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• bisoprolol
Velsipity (etrasimod)

+

bisoprolol

1 interaction

Avoid/Use Alternative

etrasimod + bisoprolol

consider alternative or monitor BP, HR, ECG, especially when adding bisoprolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• blinatumomab
Velsipity (etrasimod)

+

blinatumomab

1 interaction

Avoid/Use Alternative

etrasimod + blinatumomab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• bortezomib
Velsipity (etrasimod)

+

bortezomib

1 interaction

Avoid/Use Alternative

etrasimod + bortezomib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• brentuximab vedotin
Velsipity (etrasimod)

+

brentuximab vedotin

1 interaction

Avoid/Use Alternative

etrasimod + brentuximab vedotin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• brexucabtagene autoleucel
Velsipity (etrasimod)

+

brexucabtagene autoleucel

1 interaction

Avoid/Use Alternative

etrasimod + brexucabtagene autoleucel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• brigatinib
Velsipity (etrasimod)

+

brigatinib

1 interaction

Avoid/Use Alternative

etrasimod + brigatinib

use alternative or monitor BP, HR, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, HTN (additive effects)

• brodalumab
Velsipity (etrasimod)

+

brodalumab

1 interaction

Avoid/Use Alternative

etrasimod + brodalumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• bupivacaine
Velsipity (etrasimod)

+

bupivacaine

1 interaction

Avoid/Use Alternative

etrasimod + bupivacaine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• bupivacaine liposomal
Velsipity (etrasimod)

+

bupivacaine liposomal

1 interaction

Avoid/Use Alternative

etrasimod + bupivacaine liposomal

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• busulfan
Velsipity (etrasimod)

+

busulfan

1 interaction

Avoid/Use Alternative

etrasimod + busulfan

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• cabazitaxel
Velsipity (etrasimod)

+

cabazitaxel

1 interaction

Avoid/Use Alternative

etrasimod + cabazitaxel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• cabozantinib
Velsipity (etrasimod)

+

cabozantinib

1 interaction

Avoid/Use Alternative

etrasimod + cabozantinib

consider alternative or monitor BP, HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, HTN (additive effects)

• canakinumab
Velsipity (etrasimod)

+

canakinumab

1 interaction

Avoid/Use Alternative

etrasimod + canakinumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• carbamazepine
Velsipity (etrasimod)

+

carbamazepine

1 interaction

Avoid/Use Alternative

etrasimod + carbamazepine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may decr. etrasimod levels, efficacy; may incr. risk of PR interval prolongation, AV block, bradycardia (hepatic metab. induced; additive effects)

• carboplatin
Velsipity (etrasimod)

+

carboplatin

1 interaction

Avoid/Use Alternative

etrasimod + carboplatin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• carfilzomib
Velsipity (etrasimod)

+

carfilzomib

1 interaction

Avoid/Use Alternative

etrasimod + carfilzomib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of HTN, serious infection; infection risk may be prolonged (additive effects)

• carmustine
Velsipity (etrasimod)

+

carmustine

1 interaction

Avoid/Use Alternative

etrasimod + carmustine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• carteolol ophthalmic
Velsipity (etrasimod)

+

carteolol ophthalmic

1 interaction

Avoid/Use Alternative

etrasimod + carteolol ophthalmic

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• carvedilol
Velsipity (etrasimod)

+

carvedilol

1 interaction

Avoid/Use Alternative

etrasimod + carvedilol

consider alternative or monitor BP, HR, ECG, especially when adding carvedilol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• ceritinib
Velsipity (etrasimod)

+

ceritinib

1 interaction

Avoid/Use Alternative

etrasimod + ceritinib

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, use alternative or monitor BP, HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• certolizumab pegol
Velsipity (etrasimod)

+

certolizumab pegol

1 interaction

Avoid/Use Alternative

etrasimod + certolizumab pegol

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• chlorambucil
Velsipity (etrasimod)

+

chlorambucil

1 interaction

Avoid/Use Alternative

etrasimod + chlorambucil

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• chloramphenicol
Velsipity (etrasimod)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

etrasimod + chloramphenicol

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• chloroprocaine
Velsipity (etrasimod)

+

chloroprocaine

1 interaction

Avoid/Use Alternative

etrasimod + chloroprocaine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• chloroquine
Velsipity (etrasimod)

+

chloroquine

1 interaction

Avoid/Use Alternative

etrasimod + chloroquine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• ciltacabtagene autoleucel
Velsipity (etrasimod)

+

ciltacabtagene autoleucel

1 interaction

Avoid/Use Alternative

etrasimod + ciltacabtagene autoleucel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• cimetidine
Velsipity (etrasimod)

+

cimetidine

1 interaction

Avoid/Use Alternative

etrasimod + cimetidine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• ciprofloxacin
Velsipity (etrasimod)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

etrasimod + ciprofloxacin

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• cisapride
Velsipity (etrasimod)

+

cisapride

1 interaction

Avoid/Use Alternative

etrasimod + cisapride

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• cisplatin
Velsipity (etrasimod)

+

cisplatin

1 interaction

Avoid/Use Alternative

etrasimod + cisplatin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• citalopram
Velsipity (etrasimod)

+

citalopram

1 interaction

Avoid/Use Alternative

etrasimod + citalopram

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• cladribine injection
Velsipity (etrasimod)

+

cladribine injection

1 interaction

Avoid/Use Alternative

etrasimod + cladribine injection

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• cladribine oral
Velsipity (etrasimod)

+

cladribine oral

1 interaction

Avoid/Use Alternative

etrasimod + cladribine oral

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• clarithromycin
Velsipity (etrasimod)

+

clarithromycin

1 interaction

Avoid/Use Alternative

etrasimod + clarithromycin

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• clobetasol ophthalmic
Velsipity (etrasimod)

+

clobetasol ophthalmic

1 interaction

Avoid/Use Alternative

etrasimod + clobetasol ophthalmic

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• clofarabine
Velsipity (etrasimod)

+

clofarabine

1 interaction

Avoid/Use Alternative

etrasimod + clofarabine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• clofazimine
Velsipity (etrasimod)

+

clofazimine

1 interaction

Avoid/Use Alternative

etrasimod + clofazimine

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• clonidine
Velsipity (etrasimod)

+

clonidine

1 interaction

Avoid/Use Alternative

etrasimod + clonidine

if ADHD use, avoid combo; otherwise, monitor BP, HR, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• clopidogrel
Velsipity (etrasimod)

+

clopidogrel

1 interaction

Avoid/Use Alternative

etrasimod + clopidogrel

if CYP2C9 poor metabolizer, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• clozapine
Velsipity (etrasimod)

+

clozapine

1 interaction

Avoid/Use Alternative

etrasimod + clozapine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• cobicistat
Velsipity (etrasimod)

+

cobicistat

1 interaction

Avoid/Use Alternative

etrasimod + cobicistat

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• conivaptan
Velsipity (etrasimod)

+

conivaptan

1 interaction

Avoid/Use Alternative

etrasimod + conivaptan

during and x7 days after conivaptan tx: if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• copanlisib
Velsipity (etrasimod)

+

copanlisib

1 interaction

Avoid/Use Alternative

etrasimod + copanlisib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of HTN, serious infection; infection risk may be prolonged (additive effects; copanlisib may cause infusion-related HTN)

• corticotropin
Velsipity (etrasimod)

+

corticotropin

1 interaction

Avoid/Use Alternative

etrasimod + corticotropin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of HTN, serious infection; infection risk may be prolonged (additive effects)

• crizotinib
Velsipity (etrasimod)

+

crizotinib

1 interaction

Avoid/Use Alternative

etrasimod + crizotinib

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, use alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• crovalimab
Velsipity (etrasimod)

+

crovalimab

1 interaction

Avoid/Use Alternative

etrasimod + crovalimab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• cyclophosphamide
Velsipity (etrasimod)

+

cyclophosphamide

1 interaction

Avoid/Use Alternative

etrasimod + cyclophosphamide

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• cyclosporine
Velsipity (etrasimod)

+

cyclosporine

1 interaction

Avoid/Use Alternative

etrasimod + cyclosporine

avoid combo during and x5wk after etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection (infection risk may be prolonged), HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• cytarabine
Velsipity (etrasimod)

+

cytarabine

1 interaction

Avoid/Use Alternative

etrasimod + cytarabine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• dactinomycin
Velsipity (etrasimod)

+

dactinomycin

1 interaction

Avoid/Use Alternative

etrasimod + dactinomycin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• danazol
Velsipity (etrasimod)

+

danazol

1 interaction

Avoid/Use Alternative

etrasimod + danazol

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, monitor BP: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• danicopan
Velsipity (etrasimod)

+

danicopan

1 interaction

Avoid/Use Alternative

etrasimod + danicopan

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• daratumumab
Velsipity (etrasimod)

+

daratumumab

1 interaction

Avoid/Use Alternative

etrasimod + daratumumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• darunavir
Velsipity (etrasimod)

+

darunavir

1 interaction

Avoid/Use Alternative

etrasimod + darunavir

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• daunorubicin
Velsipity (etrasimod)

+

daunorubicin

1 interaction

Avoid/Use Alternative

etrasimod + daunorubicin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• decitabine
Velsipity (etrasimod)

+

decitabine

1 interaction

Avoid/Use Alternative

etrasimod + decitabine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• deferasirox
Velsipity (etrasimod)

+

deferasirox

1 interaction

Avoid/Use Alternative

etrasimod + deferasirox

if CYP2C9 poor metabolizer, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• degarelix
Velsipity (etrasimod)

+

degarelix

1 interaction

Avoid/Use Alternative

etrasimod + degarelix

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Velsipity (etrasimod)

+

desflurane

1 interaction

Avoid/Use Alternative

etrasimod + desflurane

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Velsipity (etrasimod)

+

desipramine

1 interaction

Avoid/Use Alternative

etrasimod + desipramine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• deucravacitinib
Velsipity (etrasimod)

+

deucravacitinib

1 interaction

Avoid/Use Alternative

etrasimod + deucravacitinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• deuruxolitinib
Velsipity (etrasimod)

+

deuruxolitinib

1 interaction

Avoid/Use Alternative

etrasimod + deuruxolitinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• dexmedetomidine
Velsipity (etrasimod)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

etrasimod + dexmedetomidine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Velsipity (etrasimod)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

etrasimod + dexmedetomidine injection

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• digoxin
Velsipity (etrasimod)

+

digoxin

1 interaction

Avoid/Use Alternative

etrasimod + digoxin

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• diltiazem
Velsipity (etrasimod)

+

diltiazem

1 interaction

Avoid/Use Alternative

etrasimod + diltiazem

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor BP, HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT and PR interval prolongation, cardiac arrhythmias, serious infection, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metab. inhibited, additive effects; antagonistic effects)

• dimethyl fumarate
Velsipity (etrasimod)

+

dimethyl fumarate

1 interaction

Avoid/Use Alternative

etrasimod + dimethyl fumarate

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• dinutuximab
Velsipity (etrasimod)

+

dinutuximab

1 interaction

Avoid/Use Alternative

etrasimod + dinutuximab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• diroximel fumarate
Velsipity (etrasimod)

+

diroximel fumarate

1 interaction

Avoid/Use Alternative

etrasimod + diroximel fumarate

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• disopyramide
Velsipity (etrasimod)

+

disopyramide

1 interaction

Avoid/Use Alternative

etrasimod + disopyramide

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT and PR interval prolongation, cardiac arrhythmias (additive effects)

• docetaxel
Velsipity (etrasimod)

+

docetaxel

1 interaction

Avoid/Use Alternative

etrasimod + docetaxel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• dofetilide
Velsipity (etrasimod)

+

dofetilide

1 interaction

Avoid/Use Alternative

etrasimod + dofetilide

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• domperidone
Velsipity (etrasimod)

+

domperidone

1 interaction

Avoid/Use Alternative

etrasimod + domperidone

use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• donepezil
Velsipity (etrasimod)

+

donepezil

1 interaction

Avoid/Use Alternative

etrasimod + donepezil

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT and PR interval prolongation, cardiac arrhythmias (additive effects)

• doxorubicin
Velsipity (etrasimod)

+

doxorubicin

1 interaction

Avoid/Use Alternative

etrasimod + doxorubicin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• dronedarone
Velsipity (etrasimod)

+

dronedarone

1 interaction

Avoid/Use Alternative

etrasimod + dronedarone

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, use alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT and PR interval prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• droperidol
Velsipity (etrasimod)

+

droperidol

1 interaction

Avoid/Use Alternative

etrasimod + droperidol

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• dulaglutide
Velsipity (etrasimod)

+

dulaglutide

1 interaction

Avoid/Use Alternative

etrasimod + dulaglutide

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• dupilumab
Velsipity (etrasimod)

+

dupilumab

1 interaction

Avoid/Use Alternative

etrasimod + dupilumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• duvelisib
Velsipity (etrasimod)

+

duvelisib

1 interaction

Avoid/Use Alternative

etrasimod + duvelisib

avoid combo during and x5wk after etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection (infection risk may be prolonged), other adverse effects (hepatic metab. inhibited, additive effects)

• eculizumab
Velsipity (etrasimod)

+

eculizumab

1 interaction

Avoid/Use Alternative

etrasimod + eculizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• efavirenz
Velsipity (etrasimod)

+

efavirenz

1 interaction

Avoid/Use Alternative

etrasimod + efavirenz

if also combined w/ moderate or strong CYP3A4 inhibitor, avoid combo; otherwise, caution advised: combo may incr. or decr. etrasimod levels, incr. risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects or decr. efficacy (hepatic metab. altered)

• efgartigimod alfa
Velsipity (etrasimod)

+

efgartigimod alfa

1 interaction

Avoid/Use Alternative

etrasimod + efgartigimod alfa

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• eliglustat
Velsipity (etrasimod)

+

eliglustat

1 interaction

Avoid/Use Alternative

etrasimod + eliglustat

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• elivaldogene autotemcel
Velsipity (etrasimod)

+

elivaldogene autotemcel

1 interaction

Avoid/Use Alternative

etrasimod + elivaldogene autotemcel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• elotuzumab
Velsipity (etrasimod)

+

elotuzumab

1 interaction

Avoid/Use Alternative

etrasimod + elotuzumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• elranatamab
Velsipity (etrasimod)

+

elranatamab

1 interaction

Avoid/Use Alternative

etrasimod + elranatamab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• emapalumab
Velsipity (etrasimod)

+

emapalumab

1 interaction

Avoid/Use Alternative

etrasimod + emapalumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• encorafenib
Velsipity (etrasimod)

+

encorafenib

1 interaction

Avoid/Use Alternative

etrasimod + encorafenib

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias; may decr. etrasimod levels, efficacy (additive effects; hepatic metab. induced)

• ensartinib
Velsipity (etrasimod)

+

ensartinib

1 interaction

Avoid/Use Alternative

etrasimod + ensartinib

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx; consider decr. dose or hold one or both drugs: combo may incr. risk of bradycardia (additive effects)

• epcoritamab
Velsipity (etrasimod)

+

epcoritamab

1 interaction

Avoid/Use Alternative

etrasimod + epcoritamab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ephedra
Velsipity (etrasimod)

+

ephedra

1 interaction

Avoid/Use Alternative

etrasimod + ephedra

avoid combo: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, HTN (additive effects)

• epinephrine inhaled
Velsipity (etrasimod)

+

epinephrine inhaled

1 interaction

Avoid/Use Alternative

etrasimod + epinephrine inhaled

avoid combo: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• epirubicin
Velsipity (etrasimod)

+

epirubicin

1 interaction

Avoid/Use Alternative

etrasimod + epirubicin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• eribulin
Velsipity (etrasimod)

+

eribulin

1 interaction

Avoid/Use Alternative

etrasimod + eribulin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• erythromycin
Velsipity (etrasimod)

+

erythromycin

1 interaction

Avoid/Use Alternative

etrasimod + erythromycin

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• esmolol
Velsipity (etrasimod)

+

esmolol

1 interaction

Avoid/Use Alternative

etrasimod + esmolol

consider alternative or monitor BP, HR, ECG, especially when adding esmolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• etanercept
Velsipity (etrasimod)

+

etanercept

1 interaction

Avoid/Use Alternative

etrasimod + etanercept

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• etoposide
Velsipity (etrasimod)

+

etoposide

1 interaction

Avoid/Use Alternative

etrasimod + etoposide

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• everolimus
Velsipity (etrasimod)

+

everolimus

1 interaction

Avoid/Use Alternative

etrasimod + everolimus

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• famotidine
Velsipity (etrasimod)

+

famotidine

1 interaction

Avoid/Use Alternative

etrasimod + famotidine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• fedratinib
Velsipity (etrasimod)

+

fedratinib

1 interaction

Avoid/Use Alternative

etrasimod + fedratinib

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• fentanyl
Velsipity (etrasimod)

+

fentanyl

1 interaction

Avoid/Use Alternative

etrasimod + fentanyl

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• fexinidazole
Velsipity (etrasimod)

+

fexinidazole

1 interaction

Avoid/Use Alternative

etrasimod + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after etrasimod D/C; use alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx or during and x7 days after fexinidazole tx: combo may decr. etrasimod levels, efficacy; may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• fingolimod
Velsipity (etrasimod)

+

fingolimod

1 interaction

Avoid/Use Alternative

etrasimod + fingolimod

avoid combo: combo may incr. risk of PR interval prolongation, AV block, bradycardia, HTN, serious infection (infection risk may be prolonged), other adverse effects (additive effects, duplicate tx)

• flecainide
Velsipity (etrasimod)

+

flecainide

1 interaction

Avoid/Use Alternative

etrasimod + flecainide

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT and PR interval prolongation, cardiac arrhythmias (additive effects)

• floxuridine
Velsipity (etrasimod)

+

floxuridine

1 interaction

Avoid/Use Alternative

etrasimod + floxuridine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• fluconazole
Velsipity (etrasimod)

+

fluconazole

1 interaction

Avoid/Use Alternative

etrasimod + fluconazole

avoid combo: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• fludarabine
Velsipity (etrasimod)

+

fludarabine

1 interaction

Avoid/Use Alternative

etrasimod + fludarabine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• fluorouracil
Velsipity (etrasimod)

+

fluorouracil

1 interaction

Avoid/Use Alternative

etrasimod + fluorouracil

avoid combo during and x5wk after etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection (infection risk may be prolonged), other adverse effects (hepatic metab. inhibited, additive effects)

• fosamprenavir
Velsipity (etrasimod)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

etrasimod + fosamprenavir

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• fosphenytoin
Velsipity (etrasimod)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

etrasimod + fosphenytoin

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may decr. etrasimod levels, efficacy; may incr. risk of PR interval prolongation, AV block, bradycardia (hepatic metab. induced; additive effects)

• fruquintinib
Velsipity (etrasimod)

+

fruquintinib

1 interaction

Avoid/Use Alternative

etrasimod + fruquintinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection, HTN, incl. hypertensive crisis; infection risk may be prolonged (additive effects)

• furosemide
Velsipity (etrasimod)

+

furosemide

1 interaction

Avoid/Use Alternative

etrasimod + furosemide

use alternative or monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• galantamine
Velsipity (etrasimod)

+

galantamine

1 interaction

Avoid/Use Alternative

etrasimod + galantamine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• gemcitabine
Velsipity (etrasimod)

+

gemcitabine

1 interaction

Avoid/Use Alternative

etrasimod + gemcitabine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• gemfibrozil
Velsipity (etrasimod)

+

gemfibrozil

1 interaction

Avoid/Use Alternative

etrasimod + gemfibrozil

if CYP2C9 poor metabolizer, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• gemtuzumab ozogamicin
Velsipity (etrasimod)

+

gemtuzumab ozogamicin

1 interaction

Avoid/Use Alternative

etrasimod + gemtuzumab ozogamicin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• gilteritinib
Velsipity (etrasimod)

+

gilteritinib

1 interaction

Avoid/Use Alternative

etrasimod + gilteritinib

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• glasdegib
Velsipity (etrasimod)

+

glasdegib

1 interaction

Avoid/Use Alternative

etrasimod + glasdegib

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• glofitamab
Velsipity (etrasimod)

+

glofitamab

1 interaction

Avoid/Use Alternative

etrasimod + glofitamab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• golimumab
Velsipity (etrasimod)

+

golimumab

1 interaction

Avoid/Use Alternative

etrasimod + golimumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• goserelin
Velsipity (etrasimod)

+

goserelin

1 interaction

Avoid/Use Alternative

etrasimod + goserelin

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• grapefruit
Velsipity (etrasimod)

+

grapefruit

1 interaction

Avoid/Use Alternative

etrasimod + grapefruit

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid grapefruit juice; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (GI metab. inhibited)

• guanfacine
Velsipity (etrasimod)

+

guanfacine

1 interaction

Avoid/Use Alternative

etrasimod + guanfacine

consider alternative or monitor BP, HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• guselkumab
Velsipity (etrasimod)

+

guselkumab

1 interaction

Avoid/Use Alternative

etrasimod + guselkumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• haloperidol
Velsipity (etrasimod)

+

haloperidol

1 interaction

Avoid/Use Alternative

etrasimod + haloperidol

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• histrelin
Velsipity (etrasimod)

+

histrelin

1 interaction

Avoid/Use Alternative

etrasimod + histrelin

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydroxychloroquine
Velsipity (etrasimod)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

etrasimod + hydroxychloroquine

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• hydroxyurea
Velsipity (etrasimod)

+

hydroxyurea

1 interaction

Avoid/Use Alternative

etrasimod + hydroxyurea

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• hydroxyzine
Velsipity (etrasimod)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

etrasimod + hydroxyzine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• ibritumomab tiuxetan
Velsipity (etrasimod)

+

ibritumomab tiuxetan

1 interaction

Avoid/Use Alternative

etrasimod + ibritumomab tiuxetan

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ibrutinib
Velsipity (etrasimod)

+

ibrutinib

1 interaction

Avoid/Use Alternative

etrasimod + ibrutinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of HTN, serious infection; infection risk may be prolonged (additive effects)

• ibutilide
Velsipity (etrasimod)

+

ibutilide

1 interaction

Avoid/Use Alternative

etrasimod + ibutilide

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• idarubicin
Velsipity (etrasimod)

+

idarubicin

1 interaction

Avoid/Use Alternative

etrasimod + idarubicin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• idecabtagene vicleucel
Velsipity (etrasimod)

+

idecabtagene vicleucel

1 interaction

Avoid/Use Alternative

etrasimod + idecabtagene vicleucel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• idelalisib
Velsipity (etrasimod)

+

idelalisib

1 interaction

Avoid/Use Alternative

etrasimod + idelalisib

avoid combo during and x5wk after etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection (infection risk may be prolonged), other adverse effects (hepatic metab. inhibited, additive effects)

• ifosfamide
Velsipity (etrasimod)

+

ifosfamide

1 interaction

Avoid/Use Alternative

etrasimod + ifosfamide

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• imatinib
Velsipity (etrasimod)

+

imatinib

1 interaction

Avoid/Use Alternative

etrasimod + imatinib

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• inebilizumab
Velsipity (etrasimod)

+

inebilizumab

1 interaction

Avoid/Use Alternative

etrasimod + inebilizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• infliximab
Velsipity (etrasimod)

+

infliximab

1 interaction

Avoid/Use Alternative

etrasimod + infliximab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• inotuzumab ozogamicin
Velsipity (etrasimod)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

etrasimod + inotuzumab ozogamicin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• iptacopan
Velsipity (etrasimod)

+

iptacopan

1 interaction

Avoid/Use Alternative

etrasimod + iptacopan

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• irinotecan
Velsipity (etrasimod)

+

irinotecan

1 interaction

Avoid/Use Alternative

etrasimod + irinotecan

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• isatuximab
Velsipity (etrasimod)

+

isatuximab

1 interaction

Avoid/Use Alternative

etrasimod + isatuximab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• isavuconazonium
Velsipity (etrasimod)

+

isavuconazonium

1 interaction

Avoid/Use Alternative

etrasimod + isavuconazonium

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• isoflurane
Velsipity (etrasimod)

+

isoflurane

1 interaction

Avoid/Use Alternative

etrasimod + isoflurane

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• itraconazole
Velsipity (etrasimod)

+

itraconazole

1 interaction

Avoid/Use Alternative

etrasimod + itraconazole

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo during and x2wk after itraconazole tx; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• ivabradine
Velsipity (etrasimod)

+

ivabradine

1 interaction

Avoid/Use Alternative

etrasimod + ivabradine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• ivosidenib
Velsipity (etrasimod)

+

ivosidenib

1 interaction

Avoid/Use Alternative

etrasimod + ivosidenib

consider alternative or monitor HR, ECG, electrolytes: combo may decr. etrasimod levels, efficacy; may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• ixabepilone
Velsipity (etrasimod)

+

ixabepilone

1 interaction

Avoid/Use Alternative

etrasimod + ixabepilone

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ixekizumab
Velsipity (etrasimod)

+

ixekizumab

1 interaction

Avoid/Use Alternative

etrasimod + ixekizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ketoconazole
Velsipity (etrasimod)

+

ketoconazole

1 interaction

Avoid/Use Alternative

etrasimod + ketoconazole

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo during and up to 1wk after ketoconazole tx; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• labetalol
Velsipity (etrasimod)

+

labetalol

1 interaction

Avoid/Use Alternative

etrasimod + labetalol

consider alternative or monitor BP, HR, ECG, especially when adding labetalol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• lacosamide
Velsipity (etrasimod)

+

lacosamide

1 interaction

Avoid/Use Alternative

etrasimod + lacosamide

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx or during lacosamide initiation/titration: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• lamotrigine
Velsipity (etrasimod)

+

lamotrigine

1 interaction

Avoid/Use Alternative

etrasimod + lamotrigine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• landiolol
Velsipity (etrasimod)

+

landiolol

1 interaction

Avoid/Use Alternative

etrasimod + landiolol

avoid combo: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• lanreotide
Velsipity (etrasimod)

+

lanreotide

1 interaction

Avoid/Use Alternative

etrasimod + lanreotide

consider alternative or monitor BP, HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, HTN (additive effects)

• lasmiditan
Velsipity (etrasimod)

+

lasmiditan

1 interaction

Avoid/Use Alternative

etrasimod + lasmiditan

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• lebrikizumab
Velsipity (etrasimod)

+

lebrikizumab

1 interaction

Avoid/Use Alternative

etrasimod + lebrikizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• lefamulin
Velsipity (etrasimod)

+

lefamulin

1 interaction

Avoid/Use Alternative

etrasimod + lefamulin

ORAL LEFAMULIN: if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG; IV lefamulin use OK: combo w/ oral lefamulin may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects; combo w/ IV lefamulin may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (hepatic metab. inhibited, additive effects)

• leflunomide
Velsipity (etrasimod)

+

leflunomide

1 interaction

Avoid/Use Alternative

etrasimod + leflunomide

avoid combo during and x5wk after etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection (infection risk may be prolonged), HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• lenacapavir
Velsipity (etrasimod)

+

lenacapavir

1 interaction

Avoid/Use Alternative

etrasimod + lenacapavir

during and x9mo after lenacapavir tx; if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• lenalidomide
Velsipity (etrasimod)

+

lenalidomide

1 interaction

Avoid/Use Alternative

etrasimod + lenalidomide

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• letermovir
Velsipity (etrasimod)

+

letermovir

1 interaction

Avoid/Use Alternative

etrasimod + letermovir

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• leuprolide
Velsipity (etrasimod)

+

leuprolide

1 interaction

Avoid/Use Alternative

etrasimod + leuprolide

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levobunolol ophthalmic
Velsipity (etrasimod)

+

levobunolol ophthalmic

1 interaction

Avoid/Use Alternative

etrasimod + levobunolol ophthalmic

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• levofloxacin
Velsipity (etrasimod)

+

levofloxacin

1 interaction

Avoid/Use Alternative

etrasimod + levofloxacin

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• levoketoconazole
Velsipity (etrasimod)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

etrasimod + levoketoconazole

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• lidocaine
Velsipity (etrasimod)

+

lidocaine

1 interaction

Avoid/Use Alternative

etrasimod + lidocaine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• lisocabtagene maraleucel
Velsipity (etrasimod)

+

lisocabtagene maraleucel

1 interaction

Avoid/Use Alternative

etrasimod + lisocabtagene maraleucel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• lithium
Velsipity (etrasimod)

+

lithium

1 interaction

Avoid/Use Alternative

etrasimod + lithium

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• lofexidine
Velsipity (etrasimod)

+

lofexidine

1 interaction

Avoid/Use Alternative

etrasimod + lofexidine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• lomustine
Velsipity (etrasimod)

+

lomustine

1 interaction

Avoid/Use Alternative

etrasimod + lomustine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• lonafarnib
Velsipity (etrasimod)

+

lonafarnib

1 interaction

Avoid/Use Alternative

etrasimod + lonafarnib

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, use alternative or monitor HR, ECG, electrolytes: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• loncastuximab tesirine
Velsipity (etrasimod)

+

loncastuximab tesirine

1 interaction

Avoid/Use Alternative

etrasimod + loncastuximab tesirine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• lopinavir/ritonavir
Velsipity (etrasimod)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

etrasimod + lopinavir/ ritonavir

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. or decr. etrasimod levels, incr. risk of AV block, bradycardia, QT and PR interval prolongation, cardiac arrhythmias, serious infection, other adverse effects or decr. efficacy (hepatic metab. altered, additive effects)

• lorlatinib
Velsipity (etrasimod)

+

lorlatinib

1 interaction

Avoid/Use Alternative

etrasimod + lorlatinib

consider alternative or monitor BP, HR, ECG, especially when starting or restarting etrasimod tx: combo may decr. etrasimod levels, efficacy; may incr. risk of PR interval prolongation, AV block, bradycardia, HTN (hepatic metab. induced; additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Velsipity (etrasimod)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Avoid/Use Alternative

etrasimod + lymphocyte immune globulin, anti-thymocyte globulin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• macimorelin
Velsipity (etrasimod)

+

macimorelin

1 interaction

Avoid/Use Alternative

etrasimod + macimorelin

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• mefloquine
Velsipity (etrasimod)

+

mefloquine

1 interaction

Avoid/Use Alternative

etrasimod + mefloquine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• melphalan
Velsipity (etrasimod)

+

melphalan

1 interaction

Avoid/Use Alternative

etrasimod + melphalan

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• mepivacaine
Velsipity (etrasimod)

+

mepivacaine

1 interaction

Avoid/Use Alternative

etrasimod + mepivacaine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• mercaptopurine
Velsipity (etrasimod)

+

mercaptopurine

1 interaction

Avoid/Use Alternative

etrasimod + mercaptopurine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• methadone
Velsipity (etrasimod)

+

methadone

1 interaction

Avoid/Use Alternative

etrasimod + methadone

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• methotrexate
Velsipity (etrasimod)

+

methotrexate

1 interaction

Avoid/Use Alternative

etrasimod + methotrexate

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• metoprolol
Velsipity (etrasimod)

+

metoprolol

1 interaction

Avoid/Use Alternative

etrasimod + metoprolol

consider alternative or monitor BP, HR, ECG, especially when adding metoprolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• midodrine
Velsipity (etrasimod)

+

midodrine

1 interaction

Avoid/Use Alternative

etrasimod + midodrine

use alternative or monitor BP, HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, HTN (additive effects)

• mifepristone
Velsipity (etrasimod)

+

mifepristone

1 interaction

Avoid/Use Alternative

etrasimod + mifepristone

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo w/in 14 days of daily mifepristone use; otherwise, caution advised w/in 14 days of daily mifepristone use: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• milk thistle
Velsipity (etrasimod)

+

milk thistle

1 interaction

Avoid/Use Alternative

etrasimod + milk thistle

if also combined w/ moderate or strong CYP3A4 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• mirikizumab
Velsipity (etrasimod)

+

mirikizumab

1 interaction

Avoid/Use Alternative

etrasimod + mirikizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• mitoxantrone
Velsipity (etrasimod)

+

mitoxantrone

1 interaction

Avoid/Use Alternative

etrasimod + mitoxantrone

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• mobocertinib
Velsipity (etrasimod)

+

mobocertinib

1 interaction

Avoid/Use Alternative

etrasimod + mobocertinib

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• mogamulizumab
Velsipity (etrasimod)

+

mogamulizumab

1 interaction

Avoid/Use Alternative

etrasimod + mogamulizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• momelotinib
Velsipity (etrasimod)

+

momelotinib

1 interaction

Avoid/Use Alternative

etrasimod + momelotinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• monomethyl fumarate
Velsipity (etrasimod)

+

monomethyl fumarate

1 interaction

Avoid/Use Alternative

etrasimod + monomethyl fumarate

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• mosunetuzumab
Velsipity (etrasimod)

+

mosunetuzumab

1 interaction

Avoid/Use Alternative

etrasimod + mosunetuzumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• moxifloxacin
Velsipity (etrasimod)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

etrasimod + moxifloxacin

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• mycophenolate mofetil
Velsipity (etrasimod)

+

mycophenolate mofetil

1 interaction

Avoid/Use Alternative

etrasimod + mycophenolate mofetil

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• mycophenolic acid
Velsipity (etrasimod)

+

mycophenolic acid

1 interaction

Avoid/Use Alternative

etrasimod + mycophenolic acid

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• nadolol
Velsipity (etrasimod)

+

nadolol

1 interaction

Avoid/Use Alternative

etrasimod + nadolol

consider alternative or monitor BP, HR, ECG, especially when adding nadolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• natalizumab
Velsipity (etrasimod)

+

natalizumab

1 interaction

Avoid/Use Alternative

etrasimod + natalizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• nebivolol
Velsipity (etrasimod)

+

nebivolol

1 interaction

Avoid/Use Alternative

etrasimod + nebivolol

consider alternative or monitor BP, HR, ECG, especially when adding nebivolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• nefazodone
Velsipity (etrasimod)

+

nefazodone

1 interaction

Avoid/Use Alternative

etrasimod + nefazodone

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• nelarabine
Velsipity (etrasimod)

+

nelarabine

1 interaction

Avoid/Use Alternative

etrasimod + nelarabine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• nelfinavir
Velsipity (etrasimod)

+

nelfinavir

1 interaction

Avoid/Use Alternative

etrasimod + nelfinavir

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• neostigmine
Velsipity (etrasimod)

+

neostigmine

1 interaction

Avoid/Use Alternative

etrasimod + neostigmine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• netupitant
Velsipity (etrasimod)

+

netupitant

1 interaction

Avoid/Use Alternative

etrasimod + netupitant

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• nilotinib
Velsipity (etrasimod)

+

nilotinib

1 interaction

Avoid/Use Alternative

etrasimod + nilotinib

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG, electrolytes: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• nirogacestat
Velsipity (etrasimod)

+

nirogacestat

1 interaction

Avoid/Use Alternative

etrasimod + nirogacestat

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• nitisinone
Velsipity (etrasimod)

+

nitisinone

1 interaction

Avoid/Use Alternative

etrasimod + nitisinone

if also combined w/ moderate or strong CYP3A4 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• obecabtagene autoleucel
Velsipity (etrasimod)

+

obecabtagene autoleucel

1 interaction

Avoid/Use Alternative

etrasimod + obecabtagene autoleucel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• obinutuzumab
Velsipity (etrasimod)

+

obinutuzumab

1 interaction

Avoid/Use Alternative

etrasimod + obinutuzumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ocrelizumab
Velsipity (etrasimod)

+

ocrelizumab

1 interaction

Avoid/Use Alternative

etrasimod + ocrelizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• octreotide
Velsipity (etrasimod)

+

octreotide

1 interaction

Avoid/Use Alternative

etrasimod + octreotide

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• ofatumumab
Velsipity (etrasimod)

+

ofatumumab

1 interaction

Avoid/Use Alternative

etrasimod + ofatumumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• oliceridine
Velsipity (etrasimod)

+

oliceridine

1 interaction

Avoid/Use Alternative

etrasimod + oliceridine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• ondansetron
Velsipity (etrasimod)

+

ondansetron

1 interaction

Avoid/Use Alternative

etrasimod + ondansetron

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• osimertinib
Velsipity (etrasimod)

+

osimertinib

1 interaction

Avoid/Use Alternative

etrasimod + osimertinib

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• oxaliplatin
Velsipity (etrasimod)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

etrasimod + oxaliplatin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ozanimod
Velsipity (etrasimod)

+

ozanimod

1 interaction

Avoid/Use Alternative

etrasimod + ozanimod

avoid combo: combo may incr. risk of PR interval prolongation, AV block, bradycardia, HTN (incl. hypertensive crisis), serious infection (infection risk may be prolonged), other adverse effects (additive effects, duplicate tx)

• paclitaxel
Velsipity (etrasimod)

+

paclitaxel

1 interaction

Avoid/Use Alternative

etrasimod + paclitaxel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• pacritinib
Velsipity (etrasimod)

+

pacritinib

1 interaction

Avoid/Use Alternative

etrasimod + pacritinib

consider alternative or monitor HR, ECG, electrolytes: combo may decr. etrasimod levels, efficacy; may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• paliperidone
Velsipity (etrasimod)

+

paliperidone

1 interaction

Avoid/Use Alternative

etrasimod + paliperidone

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Velsipity (etrasimod)

+

palonosetron

1 interaction

Avoid/Use Alternative

etrasimod + palonosetron

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• panobinostat
Velsipity (etrasimod)

+

panobinostat

1 interaction

Avoid/Use Alternative

etrasimod + panobinostat

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• pasireotide
Velsipity (etrasimod)

+

pasireotide

1 interaction

Avoid/Use Alternative

etrasimod + pasireotide

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• pegcetacoplan
Velsipity (etrasimod)

+

pegcetacoplan

1 interaction

Avoid/Use Alternative

etrasimod + pegcetacoplan

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• pentamidine
Velsipity (etrasimod)

+

pentamidine

1 interaction

Avoid/Use Alternative

etrasimod + pentamidine

consider alternative or monitor HR, ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• pentostatin
Velsipity (etrasimod)

+

pentostatin

1 interaction

Avoid/Use Alternative

etrasimod + pentostatin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• phenytoin
Velsipity (etrasimod)

+

phenytoin

1 interaction

Avoid/Use Alternative

etrasimod + phenytoin

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may decr. etrasimod levels, efficacy; may incr. risk of PR interval prolongation, AV block, bradycardia (hepatic metab. induced; additive effects)

• pimecrolimus topical
Velsipity (etrasimod)

+

pimecrolimus topical

1 interaction

Avoid/Use Alternative

etrasimod + pimecrolimus topical

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• pindolol
Velsipity (etrasimod)

+

pindolol

1 interaction

Avoid/Use Alternative

etrasimod + pindolol

consider alternative or monitor BP, HR, ECG, especially when adding pindolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• pirtobrutinib
Velsipity (etrasimod)

+

pirtobrutinib

1 interaction

Avoid/Use Alternative

etrasimod + pirtobrutinib

avoid combo during and x5wk after etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection (infection risk may be prolonged), other adverse effects (hepatic metab. inhibited, additive effects)

• polatuzumab vedotin
Velsipity (etrasimod)

+

polatuzumab vedotin

1 interaction

Avoid/Use Alternative

etrasimod + polatuzumab vedotin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• pomalidomide
Velsipity (etrasimod)

+

pomalidomide

1 interaction

Avoid/Use Alternative

etrasimod + pomalidomide

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ponatinib
Velsipity (etrasimod)

+

ponatinib

1 interaction

Avoid/Use Alternative

etrasimod + ponatinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of HTN, serious infection; infection risk may be prolonged (additive effects)

• ponesimod
Velsipity (etrasimod)

+

ponesimod

1 interaction

Avoid/Use Alternative

etrasimod + ponesimod

avoid combo: combo may incr. risk of PR interval prolongation, AV block, bradycardia, HTN, serious infection (infection risk may be prolonged), other adverse effects (additive effects, duplicate tx)

• posaconazole
Velsipity (etrasimod)

+

posaconazole

1 interaction

Avoid/Use Alternative

etrasimod + posaconazole

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• pozelimab
Velsipity (etrasimod)

+

pozelimab

1 interaction

Avoid/Use Alternative

etrasimod + pozelimab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• praziquantel
Velsipity (etrasimod)

+

praziquantel

1 interaction

Avoid/Use Alternative

etrasimod + praziquantel

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• procainamide
Velsipity (etrasimod)

+

procainamide

1 interaction

Avoid/Use Alternative

etrasimod + procainamide

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT and PR interval prolongation, cardiac arrhythmias (additive effects)

• procarbazine
Velsipity (etrasimod)

+

procarbazine

1 interaction

Avoid/Use Alternative

etrasimod + procarbazine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of HTN, serious infection; infection risk may be prolonged (additive effects)

• propafenone
Velsipity (etrasimod)

+

propafenone

1 interaction

Avoid/Use Alternative

etrasimod + propafenone

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT and PR interval prolongation, cardiac arrhythmias (additive effects)

• propranolol
Velsipity (etrasimod)

+

propranolol

1 interaction

Avoid/Use Alternative

etrasimod + propranolol

consider alternative or monitor BP, HR, ECG, especially when adding propranolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• pyridostigmine
Velsipity (etrasimod)

+

pyridostigmine

1 interaction

Avoid/Use Alternative

etrasimod + pyridostigmine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• quinidine (antiarrhythmic)
Velsipity (etrasimod)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

etrasimod + quinidine (antiarrhythmic)

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• quinidine (CYP2D6 inhibitor)
Velsipity (etrasimod)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

etrasimod + quinidine (CYP2D6 inhibitor)

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Velsipity (etrasimod)

+

quinine

1 interaction

Avoid/Use Alternative

etrasimod + quinine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia, AV block, QT and PR interval prolongation, cardiac arrhythmias (additive effects)

• quizartinib
Velsipity (etrasimod)

+

quizartinib

1 interaction

Avoid/Use Alternative

etrasimod + quizartinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• rabies vaccine
Velsipity (etrasimod)

+

rabies vaccine

1 interaction

Avoid/Use Alternative

etrasimod + rabies vaccine

if possible, avoid immunosuppressive tx or vaccinate at least 2wk before starting etrasimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ravulizumab
Velsipity (etrasimod)

+

ravulizumab

1 interaction

Avoid/Use Alternative

etrasimod + ravulizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• regadenoson
Velsipity (etrasimod)

+

regadenoson

1 interaction

Avoid/Use Alternative

etrasimod + regadenoson

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• regorafenib
Velsipity (etrasimod)

+

regorafenib

1 interaction

Avoid/Use Alternative

etrasimod + regorafenib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of HTN, serious infection; infection risk may be prolonged (additive effects)

• remifentanil
Velsipity (etrasimod)

+

remifentanil

1 interaction

Avoid/Use Alternative

etrasimod + remifentanil

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• remimazolam
Velsipity (etrasimod)

+

remimazolam

1 interaction

Avoid/Use Alternative

etrasimod + remimazolam

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• revumenib
Velsipity (etrasimod)

+

revumenib

1 interaction

Avoid/Use Alternative

etrasimod + revumenib

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Velsipity (etrasimod)

+

ribociclib

1 interaction

Avoid/Use Alternative

etrasimod + ribociclib

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG, electrolytes: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• rifampin
Velsipity (etrasimod)

+

rifampin

1 interaction

Avoid/Use Alternative

etrasimod + rifampin

avoid combo: combo may decr. etrasimod levels, efficacy (hepatic metab. induced)

• rilonacept
Velsipity (etrasimod)

+

rilonacept

1 interaction

Avoid/Use Alternative

etrasimod + rilonacept

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• risankizumab
Velsipity (etrasimod)

+

risankizumab

1 interaction

Avoid/Use Alternative

etrasimod + risankizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ritlecitinib
Velsipity (etrasimod)

+

ritlecitinib

1 interaction

Avoid/Use Alternative

etrasimod + ritlecitinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ritonavir
Velsipity (etrasimod)

+

ritonavir

1 interaction

Avoid/Use Alternative

etrasimod + ritonavir

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT and PR interval prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• rituximab
Velsipity (etrasimod)

+

rituximab

1 interaction

Avoid/Use Alternative

etrasimod + rituximab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• rivastigmine
Velsipity (etrasimod)

+

rivastigmine

1 interaction

Avoid/Use Alternative

etrasimod + rivastigmine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• romidepsin
Velsipity (etrasimod)

+

romidepsin

1 interaction

Avoid/Use Alternative

etrasimod + romidepsin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• ropeginterferon alfa-2b
Velsipity (etrasimod)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

etrasimod + ropeginterferon alfa-2b

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ropivacaine
Velsipity (etrasimod)

+

ropivacaine

1 interaction

Avoid/Use Alternative

etrasimod + ropivacaine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• rozanolixizumab
Velsipity (etrasimod)

+

rozanolixizumab

1 interaction

Avoid/Use Alternative

etrasimod + rozanolixizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• rucaparib
Velsipity (etrasimod)

+

rucaparib

1 interaction

Avoid/Use Alternative

etrasimod + rucaparib

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• ruxolitinib
Velsipity (etrasimod)

+

ruxolitinib

1 interaction

Avoid/Use Alternative

etrasimod + ruxolitinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ruxolitinib topical
Velsipity (etrasimod)

+

ruxolitinib topical

1 interaction

Avoid/Use Alternative

etrasimod + ruxolitinib topical

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• sarilumab
Velsipity (etrasimod)

+

sarilumab

1 interaction

Avoid/Use Alternative

etrasimod + sarilumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• satralizumab
Velsipity (etrasimod)

+

satralizumab

1 interaction

Avoid/Use Alternative

etrasimod + satralizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• secukinumab
Velsipity (etrasimod)

+

secukinumab

1 interaction

Avoid/Use Alternative

etrasimod + secukinumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• selinexor
Velsipity (etrasimod)

+

selinexor

1 interaction

Avoid/Use Alternative

etrasimod + selinexor

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• selpercatinib
Velsipity (etrasimod)

+

selpercatinib

1 interaction

Avoid/Use Alternative

etrasimod + selpercatinib

if CYP2C9 poor metabolizer, avoid combo; otherwise, consider alternative or monitor BP, HR, ECG, electrolytes: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• sevoflurane
Velsipity (etrasimod)

+

sevoflurane

1 interaction

Avoid/Use Alternative

etrasimod + sevoflurane

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• siltuximab
Velsipity (etrasimod)

+

siltuximab

1 interaction

Avoid/Use Alternative

etrasimod + siltuximab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• siponimod
Velsipity (etrasimod)

+

siponimod

1 interaction

Avoid/Use Alternative

etrasimod + siponimod

avoid combo: combo may incr. risk of PR interval prolongation, AV block, bradycardia, HTN, serious infection (infection risk may be prolonged), other adverse effects (additive effects, duplicate tx)

• sirolimus
Velsipity (etrasimod)

+

sirolimus

1 interaction

Avoid/Use Alternative

etrasimod + sirolimus

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• sirolimus albumin-bound
Velsipity (etrasimod)

+

sirolimus albumin-bound

1 interaction

Avoid/Use Alternative

etrasimod + sirolimus albumin-bound

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• sotalol
Velsipity (etrasimod)

+

sotalol

1 interaction

Avoid/Use Alternative

etrasimod + sotalol

use alternative or monitor HR, ECG, especially when adding sotalol to existing etrasimod tx: combo may incr. risk of bradycardia, AV block, QT and PR interval prolongation, cardiac arrhythmias (additive effects)

• spesolimab
Velsipity (etrasimod)

+

spesolimab

1 interaction

Avoid/Use Alternative

etrasimod + spesolimab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• succinylcholine
Velsipity (etrasimod)

+

succinylcholine

1 interaction

Avoid/Use Alternative

etrasimod + succinylcholine

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• sufentanil
Velsipity (etrasimod)

+

sufentanil

1 interaction

Avoid/Use Alternative

etrasimod + sufentanil

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• sugammadex
Velsipity (etrasimod)

+

sugammadex

1 interaction

Avoid/Use Alternative

etrasimod + sugammadex

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• sulfasalazine
Velsipity (etrasimod)

+

sulfasalazine

1 interaction

Avoid/Use Alternative

etrasimod + sulfasalazine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• sutimlimab
Velsipity (etrasimod)

+

sutimlimab

1 interaction

Avoid/Use Alternative

etrasimod + sutimlimab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• tacrolimus
Velsipity (etrasimod)

+

tacrolimus

1 interaction

Avoid/Use Alternative

etrasimod + tacrolimus

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of HTN, serious infection; infection risk may be prolonged (additive effects)

• tafasitamab
Velsipity (etrasimod)

+

tafasitamab

1 interaction

Avoid/Use Alternative

etrasimod + tafasitamab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• talquetamab
Velsipity (etrasimod)

+

talquetamab

1 interaction

Avoid/Use Alternative

etrasimod + talquetamab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• tarlatamab
Velsipity (etrasimod)

+

tarlatamab

1 interaction

Avoid/Use Alternative

etrasimod + tarlatamab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• teclistamab
Velsipity (etrasimod)

+

teclistamab

1 interaction

Avoid/Use Alternative

etrasimod + teclistamab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• telavancin
Velsipity (etrasimod)

+

telavancin

1 interaction

Avoid/Use Alternative

etrasimod + telavancin

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• temozolomide
Velsipity (etrasimod)

+

temozolomide

1 interaction

Avoid/Use Alternative

etrasimod + temozolomide

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• temsirolimus
Velsipity (etrasimod)

+

temsirolimus

1 interaction

Avoid/Use Alternative

etrasimod + temsirolimus

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• teplizumab
Velsipity (etrasimod)

+

teplizumab

1 interaction

Avoid/Use Alternative

etrasimod + teplizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• teriflunomide
Velsipity (etrasimod)

+

teriflunomide

1 interaction

Avoid/Use Alternative

etrasimod + teriflunomide

avoid combo during and x5wk after etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection (infection risk may be prolonged), HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• tetrabenazine
Velsipity (etrasimod)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

etrasimod + tetrabenazine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• thalidomide
Velsipity (etrasimod)

+

thalidomide

1 interaction

Avoid/Use Alternative

etrasimod + thalidomide

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of bradycardia (additive effects)

• thioguanine
Velsipity (etrasimod)

+

thioguanine

1 interaction

Avoid/Use Alternative

etrasimod + thioguanine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• thiotepa
Velsipity (etrasimod)

+

thiotepa

1 interaction

Avoid/Use Alternative

etrasimod + thiotepa

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ticagrelor
Velsipity (etrasimod)

+

ticagrelor

1 interaction

Avoid/Use Alternative

etrasimod + ticagrelor

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• tildrakizumab
Velsipity (etrasimod)

+

tildrakizumab

1 interaction

Avoid/Use Alternative

etrasimod + tildrakizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• timolol
Velsipity (etrasimod)

+

timolol

1 interaction

Avoid/Use Alternative

etrasimod + timolol

consider alternative or monitor BP, HR, ECG, especially when adding timolol to existing etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• timolol ophthalmic
Velsipity (etrasimod)

+

timolol ophthalmic

1 interaction

Avoid/Use Alternative

etrasimod + timolol ophthalmic

consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• tipranavir
Velsipity (etrasimod)

+

tipranavir

1 interaction

Avoid/Use Alternative

etrasimod + tipranavir

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• tisagenlecleucel
Velsipity (etrasimod)

+

tisagenlecleucel

1 interaction

Avoid/Use Alternative

etrasimod + tisagenlecleucel

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• tocilizumab
Velsipity (etrasimod)

+

tocilizumab

1 interaction

Avoid/Use Alternative

etrasimod + tocilizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• tofacitinib
Velsipity (etrasimod)

+

tofacitinib

1 interaction

Avoid/Use Alternative

etrasimod + tofacitinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• topotecan
Velsipity (etrasimod)

+

topotecan

1 interaction

Avoid/Use Alternative

etrasimod + topotecan

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• toremifene
Velsipity (etrasimod)

+

toremifene

1 interaction

Avoid/Use Alternative

etrasimod + toremifene

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• tralokinumab
Velsipity (etrasimod)

+

tralokinumab

1 interaction

Avoid/Use Alternative

etrasimod + tralokinumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• tramadol
Velsipity (etrasimod)

+

tramadol

1 interaction

Avoid/Use Alternative

etrasimod + tramadol

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• triclabendazole
Velsipity (etrasimod)

+

triclabendazole

1 interaction

Avoid/Use Alternative

etrasimod + triclabendazole

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Velsipity (etrasimod)

+

trifluridine

1 interaction

Avoid/Use Alternative

etrasimod + trifluridine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• triptorelin
Velsipity (etrasimod)

+

triptorelin

1 interaction

Avoid/Use Alternative

etrasimod + triptorelin

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tucatinib
Velsipity (etrasimod)

+

tucatinib

1 interaction

Avoid/Use Alternative

etrasimod + tucatinib

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• ublituximab
Velsipity (etrasimod)

+

ublituximab

1 interaction

Avoid/Use Alternative

etrasimod + ublituximab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• upadacitinib
Velsipity (etrasimod)

+

upadacitinib

1 interaction

Avoid/Use Alternative

etrasimod + upadacitinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ustekinumab
Velsipity (etrasimod)

+

ustekinumab

1 interaction

Avoid/Use Alternative

etrasimod + ustekinumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• vandetanib
Velsipity (etrasimod)

+

vandetanib

1 interaction

Avoid/Use Alternative

etrasimod + vandetanib

use alternative or monitor BP, HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, HTN (additive effects)

• vedolizumab
Velsipity (etrasimod)

+

vedolizumab

1 interaction

Avoid/Use Alternative

etrasimod + vedolizumab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• vemurafenib
Velsipity (etrasimod)

+

vemurafenib

1 interaction

Avoid/Use Alternative

etrasimod + vemurafenib

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• venetoclax
Velsipity (etrasimod)

+

venetoclax

1 interaction

Avoid/Use Alternative

etrasimod + venetoclax

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• verapamil
Velsipity (etrasimod)

+

verapamil

1 interaction

Avoid/Use Alternative

etrasimod + verapamil

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor BP, HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT and PR interval prolongation, cardiac arrhythmias, serious infection, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metab. inhibited, additive effects; antagonistic effects)

• vilobelimab
Velsipity (etrasimod)

+

vilobelimab

1 interaction

Avoid/Use Alternative

etrasimod + vilobelimab

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• vinblastine
Velsipity (etrasimod)

+

vinblastine

1 interaction

Avoid/Use Alternative

etrasimod + vinblastine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• vincristine
Velsipity (etrasimod)

+

vincristine

1 interaction

Avoid/Use Alternative

etrasimod + vincristine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• vinorelbine
Velsipity (etrasimod)

+

vinorelbine

1 interaction

Avoid/Use Alternative

etrasimod + vinorelbine

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• voclosporin
Velsipity (etrasimod)

+

voclosporin

1 interaction

Avoid/Use Alternative

etrasimod + voclosporin

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of HTN, serious infection; infection risk may be prolonged (additive effects)

• voriconazole
Velsipity (etrasimod)

+

voriconazole

1 interaction

Avoid/Use Alternative

etrasimod + voriconazole

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• zanubrutinib
Velsipity (etrasimod)

+

zanubrutinib

1 interaction

Avoid/Use Alternative

etrasimod + zanubrutinib

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• zilucoplan
Velsipity (etrasimod)

+

zilucoplan

1 interaction

Avoid/Use Alternative

etrasimod + zilucoplan

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• ziprasidone
Velsipity (etrasimod)

+

ziprasidone

1 interaction

Avoid/Use Alternative

etrasimod + ziprasidone

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)